US OptionsDetailed Quotes
ITCI250117P85000
- 0.05
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume216 Open Interest85.00Strike Price0.00Turnover6756.86%IV32.69%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0069Delta0.0009Gamma2524.00Leverage Ratio-81.1662Theta0.0000Rho-17.51Eff Leverage0.0001Vega
Intra-Cellular Therapies Stock Discussion
Sign in to post a comment
$Johnson & Johnson (JNJ.US)$ will report Q4 numbers next Wednesday (Jan. 22) at a time when the medical company’s stock has been under the weather, falling back some 14% since early September even as the S&P 500 gained about 7%. What does JNJ's technical and fundamental analysis say could happen from here?
Let's look:
Johnson & Johnson's Fundamental Analysis
The Street is looking for JNJ to report $2.04 in adjusted Q4 earnings per sha...
Let's look:
Johnson & Johnson's Fundamental Analysis
The Street is looking for JNJ to report $2.04 in adjusted Q4 earnings per sha...
22
2
Overall, the market pulled a fast one on traders on Monday. The S&P 500 started down but built into a climb by the end of the day.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.16%, the $Dow Jones Industrial Average (.DJI.US)$ was climbing 0.86%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.38%.
MACRO
In macroeconomic news this week, watch for Fed speakers, CPI inflation data on Wednesday, and Retail sale data on Thursday.
SECTORS
This week is the s...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ climbed 0.16%, the $Dow Jones Industrial Average (.DJI.US)$ was climbing 0.86%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 0.38%.
MACRO
In macroeconomic news this week, watch for Fed speakers, CPI inflation data on Wednesday, and Retail sale data on Thursday.
SECTORS
This week is the s...
40
5
10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Columns Live Stock News: Monday Market Falling, 'Too Big to Fail' Earnings to Start Q1 Report Season
Happy Monday, January 13th. The market began the week falling, but you'll never guess why: here's the Live Stock news.
$Moderna (MRNA.US)$ is falling 21% on Monday, the lowest percentage decliner on the S&P 500 after the firm updated its 2025 guidance, slashing its sales and revenue guidance by $1B, from a range of $2.5-$3.5B it gave in Sept.
$Micron Technology (MU.US)$ was one of the largest percentage ...
$Moderna (MRNA.US)$ is falling 21% on Monday, the lowest percentage decliner on the S&P 500 after the firm updated its 2025 guidance, slashing its sales and revenue guidance by $1B, from a range of $2.5-$3.5B it gave in Sept.
$Micron Technology (MU.US)$ was one of the largest percentage ...
26
7
6
Red is 
Mad!!
$Intra-Cellular Therapies (ITCI.US)$ am i buy too high at $125?
2
Morning Movers
Gapping up
$Lululemon Athletica (LULU.US)$ shares climbed 3.9% after the company raised its current-quarter targets, driven by strong holiday-season demand for its apparel.
$Enfusion (ENFN.US)$ shares surged 12% after Clearwater Analytics (NYSE:CWAN), which rose 1.7%, announced a $1.5 billion cash-and-stock acquisition of the investment management platform.
$Intra-Cellular Therapies (ITCI.US)$ shares skyrocketed 35% ...
Gapping up
$Lululemon Athletica (LULU.US)$ shares climbed 3.9% after the company raised its current-quarter targets, driven by strong holiday-season demand for its apparel.
$Enfusion (ENFN.US)$ shares surged 12% after Clearwater Analytics (NYSE:CWAN), which rose 1.7%, announced a $1.5 billion cash-and-stock acquisition of the investment management platform.
$Intra-Cellular Therapies (ITCI.US)$ shares skyrocketed 35% ...
35
6
10
$Intra-Cellular Therapies (ITCI.US)$ love this news lets make money
$Quoin Pharmaceuticals (QNRX.US)$ $Bridger Aerospace (BAER.US)$ $Mill City Ventures III (MCVT.US)$ $Elevation Oncology (ELEV.US)$ $Arcutis Biotherapeutics (ARQT.US)$ $QMMM Holdings (QMMM.US)$ $Heramba Electric (PITA.US)$ $Black Diamond Therapeutics (BDTX.US)$ $Intra-Cellular Therapies (ITCI.US)$ $Traws Pharma (TRAW.US)$ $Sage Therapeutics (SAGE.US)$ $Glucotrack (GCTK.US)$ $Algorhythm (RIME.US)$ $Agape ATP (ATPC.US)$
📊⚡️📊
📊⚡️📊
4
1
Columns Scribblings of a madman!
Ready for some research results?
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.
Summary: XTNT is really undervalued and oversold. Also, ITCI, I guess. Not LLY though, fuck them.
4
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3 ...
$Intra-Cellular Therapies (ITCI.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$Hutchmed (China) (HCM.US)$ Phase 3
$Viracta Therapeutics (VIRX.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Marinus Pharmaceuticals (MRNS.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3 ...
16
4
Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.
2
No comment yet
Benson_188 : moomoo 2025 Spring Festival red envelope! Test your luck and win up to 888* >> https://j.moomoo.com/023qve
CNNT : Enjoy reading about these stocks that are not on hype-seeking investors' radar. TQ.